

## The Use of Antibacterial Drugs for Serious Infections Approved Through Streamlined Approaches: Understanding Patient & Physician Perspectives and Considerations to Take Forward

Multi-Stakeholder Expert Meeting | March 1, 2016 | Silver Spring, MD

Meeting Participants	Affiliation
Diane Bloom	InFocus Research
Sara Calvert	Clinical Trials Transformation Initiative
Luke Chen	Duke University of Medicine
Laura Cleveland	Ohio State University
Deborah Collyar	Patient Advocates In Research (PAIR)
Amy Corneli	Duke University of Medicine
Adelaide Doussau	National Institutes of Health
Vance Fowler	Duke University of Medicine
Ian Friedland	Achaogen
David Friedland	Wockhardt Inc.
Jennifer Goldsack	Clinical Trials Transformation Initiative
Ahimsa Govender	Duke-Margolis Center for Health Policy
Gerrit Hamre	Clinical Trials Transformation Initiative
Lauri Hicks	Centers for Disease Control and Prevention
Thomas Holland	Duke University of Medicine
Christopher Houchens	BARDA
Sara Hull	National Institutes of Health
Sarah Ikenberry	Food and Drug Administration
Sylvia Lee	Food and Drug Administration, CDER
Jeff Loutit	The Medicines Company
Jonathan McCall	Duke Clinical Research Institute
Steve Mikita	Patient Advocate
Linda Park	Food and Drug Administration, CDER
Jason Pogue	Detroit Medical Center
John Powers	George Washington University School of Medicine
Scott Proestel	Food and Drug Administration, CDER
Jamie Roberts	Clinical Trials Transformation Initiative
Keith Rodvold	University of Illinois at Chicago
Vijay Tammara	Wockhardt Inc.
Pamela Tenaerts	Clinical Trials Transformation Initiative
Jeaninie Thomas	MRSA Survivors Network
Rose Tiernan	Food and Drug Administration, CDER
Joseph Toerner	Food and Drug Administration, CDER
John Tomayko	Spero Therapeutics
Richard Wunderink	Northwestern University Feinberg School of Medicine